Neoadjuvant fractionated versus hypofractionated chemoradiotherapy in resectable and borderline resectable pancreatic cancer

被引：0
|
作者：
Lee, Darren
Nelson, Bailey
Rai, Shesh
Rai, Jayesh
Wang, Kyle
Sohal, Davendra
Olowokure, Olugbenga Olanrele
Rojan, Adam
Patel, Sameer H.
Wilson, Gregory
Ahmad, Syed A.
Kharofa, Jordan
机构：
[1] Univ Cincinnati, Canc Ctr, Cincinnati, OH USA
[2] Kettering Lab Complex, Cincinnati, OH USA
[3] Univ Cincinnati, Div Hematol Oncol, Canc Ctr, Cincinnati, OH USA
[4] Univ Cincinnati, Cincinnati, OH USA
[5] Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4161
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma
    Coveler, Andrew L.
    Pillarisetty, Venu G.
    Koh, Wui-Jin
    Zhen, David B.
    Park, James O.
    King, Gentry G.
    Sham, Jonathan G.
    Hannan, Lindsay M.
    Mann, Gary N.
    Baker, Kelsey K.
    Redman, Mary W.
    Swanson, Paul E.
    Chiorean, E. Gabriela
    Whiting, Sam H.
    PANCREAS, 2023, 52 (05) : E282 - E287
  • [42] Outcomes of Neoadjuvant Concurrent Chemoradiotherapy in Borderline Resectable Pancreatic Cancer at a Sydney Tertiary Referral Center
    Fox, W.
    Tse, R.
    Shameem, N.
    Beale, P.
    Hruby, G.
    Sandroussi, C.
    Grimison, P.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 58 - 59
  • [43] Immunological Impact of Neoadjuvant Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Yuki Homma
    Koichi Taniguchi
    Takashi Murakami
    Kazuya Nakagawa
    Masatoshi Nakazawa
    Ryusei Matsuyama
    Ryutaro Mori
    Kazuhisa Takeda
    Michio Ueda
    Yasushi Ichikawa
    Kuniya Tanaka
    Itaru Endo
    Annals of Surgical Oncology, 2014, 21 : 670 - 676
  • [44] Immunological Impact of Neoadjuvant Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Homma, Yuki
    Taniguchi, Koichi
    Murakami, Takashi
    Nakagawa, Kazuya
    Nakazawa, Masatoshi
    Matsuyama, Ryusei
    Mori, Ryutaro
    Takeda, Kazuhisa
    Ueda, Michio
    Ichikawa, Yasushi
    Tanaka, Kuniya
    Endo, Itaru
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (02) : 670 - 676
  • [45] Neoadjuvant chemoradiotherapy (CRT) versus immediate surgery for resectable and borderline resectable pancreatic cancer: meta-analysis and trial sequential analysis of randomised controlled trials
    Latif, Sadia
    Hajibandeh, Shahin
    Satyadas, Thomas
    Hajibandeh, Shahab
    BRITISH JOURNAL OF SURGERY, 2022, 109
  • [46] Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer
    Suto, Hironobu
    Okano, Keiichi
    Oshima, Minoru
    Ando, Yasuhisa
    Matsukawa, Hiroyuki
    Takahashi, Shigeo
    Shibata, Toru
    Kamada, Hideki
    Kobara, Hideki
    Tsuji, Akihito
    Masaki, Tsutomu
    Suzuki, Yasuyuki
    PANCREAS, 2022, 51 (03) : 269 - 277
  • [47] Role of Chemoradiotherapy in the Adjuvant and Neoadjuvant Settings for Resectable Pancreatic Cancer
    Sen, N.
    Falk, S.
    Abrams, R. A.
    CLINICAL ONCOLOGY, 2014, 26 (09) : 551 - 559
  • [48] Neoadjuvant Chemotherapy Efficacy and Safety in Borderline Resectable Pancreatic Cancer
    He, X.
    Zheng, Y.
    Wang, Jiabao
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 85 : 62 - 66
  • [49] Landmark Series: Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer
    Jin He
    Richard D. Schulick
    Marco Del Chiaro
    Annals of Surgical Oncology, 2021, 28 : 1514 - 1520
  • [50] Updates on the Use of Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer
    Chandhok, Namrata Sonia
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2014, 15 (02): : 91 - 94
12345